WEN LEANA sold $88K of GKOS

WEN LEANA sold 525 shares of GLAUKOS Corp (GKOS) at $167.63 on 2026-07-31.

Original reporting
SEC EDGAR · WEN LEANA
Published Aug 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest fact is the reported open-market sale size, price, and post-transaction holdings for a director. It does not include any operational or financial guidance changes.

02

Market read

Traders may note insider selling for sentiment monitoring, but the disclosed value (~$88K) is unlikely to be a standalone catalyst.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says none), but it also provides no context on total holdings, prior sales cadence, or reasons for the transaction.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-03, transaction dated 2026-07-31.

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp (GKOS).

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos director Wen Leana filed a Form 4 open-market sale of 525 shares at $167.63 on 2026-07-31, worth about $88K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying corporate news, guidance, or operational catalyst in the text.

Market effects

No sector read-through is provided beyond a routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or planned liquidity needs and may not signal reduced confidence.

Key entities

  • GLAUKOS Corp

    Company whose director insider sale is disclosed via Form 4.

  • WEN LEANA

    Director reporting an open-market sale of 525 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.